(Circulation. 1995;92:2276-2283.)
© 1995 American Heart Association, Inc.
Articles |
From the Lillie Frank Abercrombie Section of Cardiology (W.J.D.), the Speros P. Martel Section of Leukocyte Biology and Inflammation Research (W.J.D., E.E.M., K.L.B.), the Department of Pediatrics, Section of Cardiovascular Sciences (W.J.D., L.H.M.), the Department of Medicine and the Center for Comparative Medicine (R.S.G.), Baylor College of Medicine, Houston, Tex.
Correspondence to William J. Dreyer, MD, Pediatric Cardiology, Texas Children's Hospital, 6621 Fannin, Houston, TX 77030.
| Abstract |
|---|
|
|
|---|
Methods and Results Fifteen adult, mixed-breed dogs underwent 90 minutes of cardiopulmonary bypass with 3 hours of subsequent recovery. Seven additional dogs were treated before cardiopulmonary bypass with a 1-mg/kg IV bolus of R15.7 IgG, a monoclonal antibody to CD18. Both groups were compared with 5 sham bypass control dogs. Bypassed dogs demonstrated an increased number of PMNs sequestered in the lungs 3 hours after bypass compared with sham bypass control dogs (1466±75 versus 516±43 PMN/mm2 alveolar surface area, mean±SEM, P<.001). Also, when PMNs from bypass dogs were compared with those from sham dogs, they produced more H2O2 (305±45 versus 144±48 amol H2O2 per phagocyte per 20 minutes, P<.05). Bypass dogs had significantly decreased arterial oxygenation 3 hours after the procedure compared with shams (457±20 versus 246±49 mm Hg, P<.05), and they had a significantly increased lung wet-to-dry weight ratio (5.38±0.14 versus 4.54±0.15, P=.003), demonstrating a significant increase in lung water. R15.7 markedly attenuated pulmonary PMN accumulation in bypass dogs (412±73 PMN/mm2, P<.001) and significantly inhibited PMN production of H2O2 (146±18 amol H2O2 per phagocyte per 20 minutes, P<.05) Bypass dogs pretreated with R15.7 also had improved oxygenation (445±28 mm Hg, P<.05) and tended to have less lung water accumulation after bypass (4.99±0.20).
Conclusions Pulmonary dysfunction after cardiopulmonary bypass is caused, at least in part, by a neutrophil-mediated, CD18-dependent mechanism.
Key Words: leukocytes lung cardiopulmonary bypass antibodies
| Introduction |
|---|
|
|
|---|
Activated cells in the peripheral blood may indicate an ongoing inflammatory response within the microvasculature of the lungs and other organs. In a recent study, we documented a significant correlation between the percentage of activated peripheral blood neutrophils (as documented by CD18 expression) and postoperative arterial oxygenation.10 From this work, it follows that neutrophil sequestration within the lungs after CPB may be CD18-dependent, and a strategy to block neutrophil adhesion in the perioperative period may help to alleviate postoperative pulmonary dysfunction. This study was performed in a canine model to test this hypothesis.
| Methods |
|---|
|
|
|---|
Three groups of
dogs were included in this study. The first group
consisted of 15 dogs that underwent CPB with an aortic cross-clamp
time of 60 minutes and total bypass time of
90 minutes. Before
cannulation, dogs were anticoagulated with 100 U/kg porcine heparin
sodium. After the aorta was cross clamped, the heart was arrested with
prograde administration of cold potassium cardioplegia, given to effect
(Plegisol, Abbott Laboratories), and the dogs were cooled to 24°C to
28°C. During CPB, hematocrit was maintained in the range of 23% to
25%, and flow was maintained at 60 to 70
mL · kg-1 · min-1 at a
pressure of 40
to 60 mm Hg. Alpha-stat pH management was observed during CPB.
After rewarming and weaning from CPB, dogs received protamine sulfate 1
mg/100 U heparin delivered for reversal of anticoagulation. Dogs were
once again ventilated with 100% oxygen. Tidal volume and ventilator
rate were returned to their original settings. Dogs were then
maintained with open chests for 3 hours while blood samples were
obtained. At no time in the recovery phase did dogs receive inotropic
support or vasodilators. In selected dogs, a small biopsy specimen was
obtained from the right upper lobe of the lung before cannulation for
CPB. In all dogs, pulmonary tissue samples were obtained at the
end of the experiment.
The second group consisted of 7 dogs that were treated in a similar fashion to that described, except just before CPB each dog received a single 1-mg/kg bolus injection of the anti-CD18 monoclonal antibody R15.7 (described below).
The third group consisted of 5 dogs designated sham bypass controls. These dogs served as controls in that they received general anesthesia and mechanical ventilation similar to the dogs in group 1. In addition, they underwent midline thoracotomies and cannula placement but were not placed on CPB. Also, these dogs were not subjected to cooling and rewarming, anticoagulation, or hemodilution, and there was no reduction of pulmonary blood flow at any time during the procedure. These dogs, however, were maintained with open chests for a duration similar to that for the dogs in group 1.
Monoclonal Antibody R15.7
R15.7 is an IgG1 murine monoclonal
antibody that recognizes a
functional epitope of the CD18 adherence glycoprotein on
both human and canine cells as previously described.15
Pharmaceutical-grade R15.7 monoclonal antibody was provided by
Boehringer-Ingelheim Pharmaceuticals, Inc. Endotoxin was
removed by passage over a polymyxin B column, and the antibody was
sterile-filtered and stored at -80°C until use.
Flow Cytometry
In dogs from all three groups, CD18 expression
was determined on
peripheral blood neutrophils by indirect
immunofluorescence with whole-blood
samples from the femoral artery. Blood samples were collected in
citrate-phosphate-dextrose buffer (1.4 mL/10 mL blood) and were
immediately fixed in 0.25% paraformaldehyde until all
samples were collected. Duplicate 100-µL aliquots were then incubated
for 15 minutes at room temperature with 10 µg/mL R15.7. The samples
were washed twice in 1 mL Dulbecco's PBS and were then incubated with
a 1:30 dilution of fluorescein-conjugated goat
anti-mouse F(ab')2 (Zymed Laboratories) for 15 minutes
at room temperature and washed once in 1 mL Dulbecco's PBS. Red blood
cells were lysed in 1.5 mL FACS lysing solution (Becton Dickinson) for
10 minutes at room temperature. The samples were then washed once in
Dulbecco's PBS, resuspended in 1% paraformaldehyde,
and stored overnight at 4°C. Samples were subsequently
analyzed in duplicate on a Becton Dickinson FACScan.
Neutrophils in suspension were gated on from light-scatter
characteristics, and fluorescence intensity was measured and
interpreted as the surface expression of the CD18 molecule.
In selected dogs from the group systemically treated with R15.7, we wished to determine the percent saturation of binding sites by the systemically administered R15.7 antibody. For this purpose, the protocol was altered as previously described.16 In this case, a duplicate set of blood samples was obtained at the indicated time points and processed immediately with no paraformaldehyde fixation. Blood samples received no primary antibody but were initially washed twice in 1 mL Dulbecco's PBS, resuspended, and then incubated with fluorescein-conjugated goat anti-mouse F(ab')2 for 15 minutes at room temperature. Samples were then handled as described above. By comparing the mean fluorescence values from the initial set of blood samples that received exogenous R15.7 with the second set of samples described above, we could determine the total number of R15.7 binding sites present on the neutrophils, the number of binding sites occupied by systemically administered R15.7, and the percent saturation of available binding sites by exogenously administered R15.7 throughout the protocol.
Also, to document the presence of R15.7 in plasma in sufficient quantity to produce antibody excess, additional blood samples from the test dogs were centrifuged at 800g for 5 minutes at room temperature, and the plasma was removed. The cell button from 100 µL whole blood drawn from a separate donor dog was suspended and incubated with either a saturating concentration of R15.7 or plasma from the test dog for 15 minutes at room temperature. The cells were washed, incubated with fluorescein-conjugated goat anti-mouse F(ab')2, and processed for flow cytometry as described above. Comparison between the samples allowed us to determine whether a saturating concentration of R15.7 remained in the plasma throughout the protocol.
White Blood Cell Counts
White blood cell counts were
determined from femoral
arterial whole-blood samples by use of an automated
counter (Coulter Electronics, Ltd). Counts obtained during and after
CPB were corrected for hemodilution with the formula
WBCcorr=WBCobsxHctbl/Hctobs,
where WBCcorr is the corrected white blood cell count,
WBCobs is the observed white blood cell count,
Hctbl is the beginning or "baseline" hematocrit, and
Hctobs is the observed hematocrit at the time of the white
blood cell count determination.
Morphometric Analysis
Canine lung tissue was immersion-fixed
in 10% buffered
zinc-formalin and embedded in paraffin, and 4-µm sections were
cut with a Leica microtome. Tissue sections were incubated with SG8H6,
an IgG1 murine monoclonal antibody to a canine neutrophilspecific
antigen,17 with standard immunohistochemical techniques
applicable to an alkaline phosphatase reporter system. The chromagen
used was nitroblue tetrazolium, and the sections were counterstained
with eosin.
Stained tissue sections were analyzed with an image analysis software program (OPTIMAS, Bioscan). Images of lung tissue were captured with a black and white camera (CCD72, Dage MTI) connected to a Leitz Diaplan microscope with frame grabber support through an ALR 486/66-MHz personal computer. The number of neutrophils in a given x40 field were distinguished by their differential gray-scale intensity compared with the eosin-counterstained lung tissue. Neutrophils were counted and expressed per cross-sectional area of alveolar air space.
Luminometry
A single photon-counting luminometer (Autolumat
LB953,
Berthold) was used to measure phagocytic hydrogen peroxide
production. Blood samples were collected in
citrate-phosphate-dextrose buffer and run within 4 hours of
collection. A 100-µL aliquot of blood was mixed with 9.9 mL
blood-diluting medium (ExOxEmis), a buffered balanced salt solution
containing 5.0 mmol 2-[N-morpholino]ethane sulfonate,
porcine gelatin (0.05% wt/vol), and the following electrolyte
composition: Na+ 142 mmol/L, K+ 5 mmol/L,
Cl- 147 mmol/L, HnPO42- 0.8 mmol/L, and
D-glucose 5.5 mmol/L, with pH 7.30 and 295-mosm/kg
osmolality. The chemilumingenic medium was a similar buffered balanced
salt solution with added calcium (1.3 mmol/L
Ca2+), magnesium (0.9 mmol/L
Mg2+), and 0.15 mmol/L luminol
(5-amino-2,3,-dihydro-1,4-phtalazinedione) as the chemiluminigenic
substrate.
Human complement opsonized zymosan (100 µL) was added to optical-quality polystyrene tubes (ExOxEmis) that had been coated with platelet-activating factor (10-9 mol/L). Platelet-activating factor was used as a priming stimulus and zymosan as a phagocytic substrate to stimulate the respiratory burst activity of neutrophils. Automatic injectors dispensed first 100 µL of blood-diluting medium containing test blood and then 600 µL chemiluminigenic substrate into these tubes. Photon counts were measured for 30 minutes and were plotted against time. The integral from 0 to 20 minutes was used to calculate the luminescence activity (counts per phagocyte) and hydrogen peroxide production (attomoles H2O2 per phagocyte), a method based on the method of Stevens et al.18
Systemic Oxygenation
The change in arterial oxygen tension
over the
course of the experiment was measured as a marker of pulmonary
dysfunction. Throughout the study, all dogs were ventilated with 100%
oxygen. Tidal volume and ventilator rate were set to optimize pH and
PCO2 and were not changed subsequently. When
dogs were being weaned from CPB, their lungs were reexpanded and
hyperinflated just briefly to reestablish lung volume, but the
ventilator was then adjusted to its original settings and not altered.
Despite subsequent changes in arterial
PO2, pH and
PCO2 remained relatively constant. Given an
FIO2 of 1.0 and a relatively constant
PCO2, alveolar
PO2 was assumed to be constant, and changes
in arterial PO2 were interpreted
to represent changes in intrapulmonary shunt.
Femoral arterial blood gases and pH were determined in
standard fashion by use of a pH and blood gas analyzer (model
170, Ciba Corning Diagnostics Corp).
Wet-to-Dry Weight Ratios
The wet weight of an excised lobe of
the lung was measured
immediately after termination of the experiment. The lung tissue was
then dried in an Equatherm vacuum oven (Labline Instruments) at
130°C. After 6 hours, the lung tissue was weighed hourly until there
was no variation in weight. The wet-to-dry ratio of the lung
tissue was then calculated, and this was used as a marker of lung
water.
Statistical Analysis
For descriptive analysis, values for
individual dogs
were pooled within their designated group at the time point at which
they were measured and were expressed as mean±SEM. For the data
presented in Tables 1
and 2
and Figs
1
, 4
, and 5
, values were
measured on a repeated basis over time for each individual dog. Group
comparisons were made by use of a two-way ANOVA for repeated
measures. When ANOVA indicated a significant group-by-time
interaction, specific within-group and between-group
comparisons of different time points were made with a multiple
comparison procedure (Student-Newman-Keuls). For the data
presented in Figs 3
and 6
, a simple one-way
ANOVA was
performed. A value of P
.05 was considered significant.
|
|
|
|
|
|
|
Approval
The animal studies reported here were reviewed and
approved by
the Baylor College of Medicine Animal Care and Use Committee. These
studies conformed with the "Guide for the Care and Use of Laboratory
Animals" published by the NIH (NIH publication No. 85-23, revised
1985).
| Results |
|---|
|
|
|---|
Peripheral White Blood Cell Counts
Mean peripheral white
blood cell counts were
comparable between groups before thoracotomy (6495±1188,
5995±809,
and 7941±662 cells/mm3 for sham, CPB, and CPB+R15.7
dogs,
respectively; P=NS). After thoracotomy,
peripheral white blood cell counts in all groups dropped
25% (Fig 1
). In the sham controls, there was a
subsequent rise in white blood cell count throughout the duration of
the protocol. In dogs undergoing CPB, there was a significant drop in
white blood cell count during extracorporeal circulation to
35% of
baseline levels. This decrease in white blood cell count during CPB was
similar in both untreated and R15.7-treated dogs. In both groups, white
blood cell counts began to recover immediately after CPB. In the
untreated group, white blood cell count rose more slowly throughout the
protocol than in the R15.7-treated group, perhaps indicative of greater
leukocyte sequestration in peripheral vascular beds. The
difference between untreated and R15.7-treated dogs, however, did not
reach statistical significance.
Pulmonary Neutrophil Sequestration
As Fig 2
demonstrates, neutrophils present
within alveolar capillaries were readily identified by
immunohistochemistry by use of the SG8H6 antibody. Compared with
baseline biopsy samples obtained before CPB, sham bypass controls had
no significant increase in pulmonary neutrophils at the end of
the experiment; in untreated dogs undergoing CPB, however, there was
approximately a threefold increase in sequestered neutrophils within
the lungs 3 hours after CPB (1466±75 versus 516±43 neutrophils
per 1
mm2 alveolar surface area, P<.001). In general,
very few neutrophils were noted within the alveolar space, although
after CPB single neutrophils and neutrophil aggregates (Fig 2B
,
arrows)
were noted within the alveolar capillaries. CPB dogs treated with R15.7
demonstrated a marked reduction in pulmonary neutrophil
sequestration 3 hours after CPB compared with the untreated CPB group,
and post-CPB samples had virtually the same number of neutrophils as
pre-CPB samples (Fig 3
).
|
Luminometry
Our luminometry experiments were designed to
examine the
functional ability of peripheral neutrophils to produce
H2O2 in response to CPB when presented
in vitro with a substrate for phagocytosis (human
complementopsonized zymosan) and presented with a
chemotactic stimulus (platelet-activating factor). As Fig 4
shows, neutrophils from all three study groups
demonstrated a similar degree of H2O2
production before CPB. In the sham group, this
H2O2 production tended to increase over
time, although the increase was not significant. Neutrophils from
dogs undergoing CPB, however, showed a marked increase in
H2O2 production in response to CPB. The
presence of R15.7 in the serum of CPB dogs significantly attenuated
this response so that, 3 hours after CPB, H2O2
production in the R15.7-treated dogs was comparable to that
seen in shams.
Arterial Oxygenation
Baseline arterial oxygenation before
thoracotomy was similar in sham, CPB, and R15.7-treated dogs (479±25,
546±14, 494±51 mm Hg, respectively). Arterial
oxygenation in the sham controls did not change
significantly throughout the protocol, and their data are not shown.
Similarly, pH, PCO2, and hematocrit
remained comparable between CPB groups during the study and therefore
are not reported. Significant differences did occur, however, between
the arterial oxygenation patterns of the
untreated and R15.7-treated dogs (Fig 5
).
Oxygenation was similar for both groups before and
during CPB, with very efficient oxygenation occurring
during the CPB procedure. Also, with the first post-CPB sample, both
groups were close to baseline. Within 20 minutes after CPB, however,
the groups began to separate. Untreated CPB dogs had a continued
deterioration in oxygenation that appeared to plateau
between 2 and 3 hours after CPB. R15.7-treated dogs, however, showed a
slower rate of decline and a significant recovery of
oxygenation after the first post-CPB hour.
Lung Water
Wet-to-dry weight ratios were determined in lung
specimens
obtained at the end of the experiment as an estimate of lung water. As
Fig 6
demonstrates, CPB dogs had a significant increase
in lung water compared with shams. This increase appeared to be
attenuated in CPB dogs treated with R15.7, but the difference between
R15.7-treated and untreated CPB dogs did not reach statistical
significance.
Hemodynamics
Finally, hemodynamic parameters,
including heart rate, mean systemic arterial pressure, mean
pulmonary arterial pressure, and mean left atrial
pressure, were measured in each of the study groups (Table 2
).
Mean left atrial pressure and mean pulmonary
artery pressure were low and remained low in all groups throughout the
study protocol. After CPB, heart rate and mean systemic
arterial pressure were significantly decreased compared
with baseline values in both R15.7-treated and untreated dogs. Post-CPB
heart rates, however, were not different between the two groups. The
R15.7-treated dogs tended to have a higher systemic
arterial pressure after CPB than the untreated group,
although this difference was not statistically significant.
Hemodynamic changes did not correlate with changes in
the other parameters noted above.
| Discussion |
|---|
|
|
|---|
The CD11/CD18 complex has been shown to be fundamentally important to the margination and emigration of neutrophils at inflammatory sites and to the adhesion-dependent release of H2O2 and elastase as mediators of target-cell injury. In models of sepsis,26 27 hemorrhagic shock,28 29 and ischemia-reperfusion,30 anti-CD18 therapy has proved to be an effective means of preventing tissue injury. It follows then that neutrophil sequestration in the lungs after CPB and the potential injury caused by endothelial cell disruption and microvascular permeability changes may, in fact, be CD18-dependent. Although increased surface expression of CD18 on circulating neutrophils has been documented in response to CPB, increased surface expression of CD18 on circulating cells alone does not translate to the participation of this molecule in sequestration of neutrophils within the microcirculation.
Verrier and Shen31 briefly reported in a limited number of primate experiments that treatment with the anti-CD18 monoclonal antibody 60.3 reduces postoperative weight gain and improves oxygenation after CPB. Gillinov et al32 reported similar results in pigs using a leumedin compound that includes among its anti-neutrophil properties the inhibition of neutrophil adhesion. The study reported here, however, provides the first detailed documentation of the use of an anti-CD18 monoclonal antibody in an animal model of CPB and clearly confirms a role for CD18 in pulmonary neutrophil sequestration after CPB. Treatment with a 1-mg/kg bolus of R15.7 before CPB resulted in a saturating concentration of antibody in the serum throughout the protocol. Antibody treatment virtually eliminated the increase in post-CPB neutrophil sequestration in the lungs and reduced neutrophil numbers back to baseline levels. In addition, anti-CD18 therapy attenuated postoperative pulmonary dysfunction. Both oxygenation and lung water accumulation were improved by treatment. This study also demonstrated that CPB can act as a priming stimulus to potentiate the release of H2O2 in circulating neutrophils. This H2O2 release also was significantly inhibited by the systemically administered antibody.
R15.7 was chosen for these experiments for two reasons. First, although R15.7 was developed from canine peritoneal macrophages, it cross-reacts with and can block the function of CD18 in a number of species, including cats,30 rabbits,33 cows,34 nonhuman primates,35 and humans.36 This cross-reactivity suggests that the antibody recognizes a fundamentally important and functional epitope of the molecule that has been well conserved across species. Second, in this study, we wanted to inhibit the broadest range of integrin-mediated functions possible. Because R15.7 recognizes CD18, or the ß subunit common to all leukocyte integrins, it can block the function of both LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). Both molecules have been demonstrated to participate in firm attachment and transendothelial migration of neutrophils. In addition, the Mac-1 molecule appears to play a fundamental role in adhesion-dependent release of H2O2 in chemotactically stimulated neutrophils.36
The applicability of these studies to therapeutic intervention in patients to reduce postoperative pulmonary dysfunction and its associated morbidity remains to be seen. Our study was limited by a short postoperative follow-up interval. Whether changes seen between treated and untreated groups within this interval would be apparent after a longer recovery time is unknown. Also, whether changes in pulmonary dysfunction seen in the model would translate to a reduced time of mechanical ventilation, a reduced recovery room stay, or reduced mortality, particularly in higher-risk patients, remains a matter of conjecture. The potential side effects of treatment also have not been fully evaluated. Nevertheless, this study suggests that anti-adhesion monoclonal antibodies may have a role in treating the postoperative CPB patient and indicates the need for further investigation of a potential new therapy.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received February 16, 1995; revision received May 1, 1995; accepted May 13, 1995.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L.-Z. Wang, S.-T. Li, Y.-T. Wang, and Z.-P. Wang Antioxidant Attenuates Acute Lung Injury After Cardiopulmonary Bypass in Rats Asian Cardiovasc Thorac Ann, February 1, 2007; 15(1): 2 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Modine, R Azzaoui, G Fayad, D Lacroix, R Bordet, H Warembourg, and T Gourlay A recovery model of minimally invasive cardiopulmonary bypass in the rat Perfusion, March 1, 2006; 21(2): 87 - 92. [Abstract] [PDF] |
||||
![]() |
B. Dixon, J. Santamaria, and D. Campbell Coagulation Activation and Organ Dysfunction Following Cardiac Surgery Chest, July 1, 2005; 128(1): 229 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-H Sievers, C. Freund-Kaas, S. Eleftheriadis, T. Fischer, H. Kuppe, E. G. Kraatz, and J.F. M. Bechtel Lung protection during total cardiopulmonary bypass by isolated lung perfusion: preliminary results of a novel perfusion strategy Ann. Thorac. Surg., October 1, 2002; 74(4): 1167 - 1172. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S.H. Ng, S. Wan, A. P.C. Yim, and A. A. Arifi Pulmonary Dysfunction After Cardiac Surgery* Chest, April 1, 2002; 121(4): 1269 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P Vallely, P. G Bannon, C. F Hughes, and L. Kritharides Endothelial Cell Adhesion Molecules and Cardiopulmonary Bypass Asian Cardiovasc Thorac Ann, December 1, 2001; 9(4): 349 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Asimakopoulos Systemic inflammation and cardiac surgery: an update Perfusion, September 1, 2001; 16(5): 353 - 360. [Abstract] [PDF] |
||||
![]() |
W. G. Kim, B.-H. Lee, and J. W. Seo Light and electron microscopic analyses for ischaemia-reperfusion lung injury in an ovine cardiopulmonary bypass model Perfusion, May 1, 2001; 16(3): 207 - 214. [Abstract] [PDF] |
||||
![]() |
O Fabre, R Zegdi, A Vincentelli, M Cambillaud, A Prat, A Carpentier, and J N Fabiani A recovery model of partial cardiopulmonary bypass in the rat Perfusion, May 1, 2001; 16(3): 215 - 220. [Abstract] [PDF] |
||||
![]() |
O. E. Arafa, O. R. Geiran, K. Andersen, E. Fosse, S. Simonsen, and J. L. Svennevig Intraaortic balloon pumping for predominantly right ventricular failure after heart transplantation Ann. Thorac. Surg., November 1, 2000; 70(5): 1587 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Asimakopoulos, R. Thompson, S. Nourshargh, E. A. Lidington, J. C. Mason, C. P. Ratnatunga, D. O. Haskard, K. M. Taylor, and R. C. Landis An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 361 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Cox Jr, S. J. Allen, H. Sauer, and J. Frederick EFFECTS OF SELECTIN-SIALYL LEWISX BLOCKADE ON MESENTERIC MICROVASCULAR PERMEABILITY ASSOCIATED WITH CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., June 1, 2000; 119(6): 1255 - 1261. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lu, K. Youker, C. Ballantyne, M. Entman, and C. W. Smith Hydrogen peroxide induces LFA-1-dependent neutrophil adherence to cardiac myocytes Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H835 - H842. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tanita, C. Song, H. Kubo, Y. Hoshikawa, S. Ueda, and S. Fujimura Superoxide possibly produced in endothelial cells mediates the neutrophil-induced lung injury Ann. Thorac. Surg., February 1, 2000; 69(2): 402 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Ilton, P. E. Langton, M. L. Taylor, N. L. A. Misso, M. Newman, P. J. Thompson, and J. Hung DIFFERENTIAL EXPRESSION OF NEUTROPHIL ADHESION MOLECULES DURING CORONARY ARTERY SURGERY WITH CARDIOPULMONARY BYPASS J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 930 - 937. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Bittner, E. P. Chen, S. S. Biswas, P. Van Trigt III, and R. D. Davis Right ventricular dysfunction after cardiac transplantation: primarily related to status of donor heart Ann. Thorac. Surg., November 1, 1999; 68(5): 1605 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Asimakopoulos, P. L.C. Smith, C. P. Ratnatunga, and K. M. Taylor Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass Ann. Thorac. Surg., September 1, 1999; 68(3): 1107 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Asimakopoulos Mechanisms of the systemic inflammatory response Perfusion, July 1, 1999; 14(4): 269 - 277. [PDF] |
||||
![]() |